AlphaThera, a startup company co-founded by Andrew Tsourkas, PhD, professor of Bioengineering and Co-Director, Center for Targeted Therapeutics and Translational Nanomedicine (CT3N), entered into an expanded license agreement with Penn to incorporate additional intellectual property focused on antibody conjugation and purification techniques, much of which resulted from an ongoing collaboration and sponsored research between the company and the Tsourkas lab at Penn. The company is currently generating revenues through commercial sales of its antibody-based research reagents, and is looking to execute on several strategic partnerships to help bring their products to a broader market.